International Biotechnol... Share Discussion Threads

[rambutan2] 30/5/2003 14:36

good move...

Intl. Biotechnology Trust PLC
30 May 2003
Purchase of Shares For Cancellation

International Biotechnology Trust plc announces that on 29 May 2003 the Company
purchased a total of 500,000 shares for cancellation at a price of 74.00 pence
per share. Following this purchase, there are a further 48,115,467 shares in
issue.

[matt1231] 28/5/2003 13:54

rambutan2,so he did.Director buying averaging up as NAV and share price rise all very positive signs.IBT share of the future I'm sure.

[rambutan2] 28/5/2003 13:19

mat231, director andrew barker was the nipper inner. hes been an active buyer over the last year – one of the few directors in the investment trust sector. nav went over 100p yesterday, the first time for a while.

[maxwellsdemon] 28/5/2003 11:49

lex1000,

The reason for the rise is probably down to the fact that the NASDAQ Biotech Index was up almost 6% last evening.

[lex1000] 28/5/2003 11:28

Have been watching and waiting hoping for fall below 70p.Moved quickly to 78p.

[matt1231] 28/5/2003 10:12

Someones nipped in with a 25K buy @ 73p.

[matt1231] 28/5/2003 08:18

rambutant2, well called no sign of weakness.Offer ticked up from 73 to 74.

[rambutan2] 27/5/2003 15:06

us bio index keeps on climbing up so no reason for price to fall.

[matt1231] 27/5/2003 14:55

Need MMs to encourage more selling to bring share price down.

[matt1231] 26/5/2003 14:11

Hoping to nip in on possible small double bottom dip offer price @ 72p.Chart suggesting to me that share price consolidating before next move up.Only needs one winner in portfolio to provide some exciting returns and new highs. Agree not forgetting investments in unlisted companies.Huge potential here.IMHO,DYOR.

[matt1231] 22/5/2003 12:42

Put IBT on my watch list waiting for opportunity to get in after profit taking and hold long term.Little known share with low activity on thread.Investment in Eyetech Pharmaceuticals interests me.NAV has contiuned rising recently.May take a pause together with share price.Looks on course to replicate 1999-2000 charts with similar uptrend.Not saying 360p,however,between 100p and 200p more than possible.Hidden gem.IMHO,DYOR

[rambutan2] 22/5/2003 09:44

agree y3. need the ipo mkts to open and sentiment to continue to improve. but when they do imho this could go up in multiples from current mkt cap. of course, if eyetech gets approval then this could all happen quicker than the mkt dictates. svls are very good and many of ibts vc holdings were taken alongside their big funds with someone on the board. i think this could be a hidden gem.

[yiyack3] 22/5/2003 01:26

This used to be a well known gem. Hammered for 2 years due to the extremely low sentiment about biotechs that don't yet have a product. It normally follows the Nasdaq quite well, the recent outperformance has been due to Nasdaq rise plus correction of the discount to the NAV which got to almost 35%.

Don't expect a dip due to profit taking unless the Nasdaq dips. If the Nas goes down a lot from here, as the bears predict, IBT's price will go down with the Nas plus will weaken to a wider discount. If the Nas rallies, IBT's price will continue to outperform as the discount narrows.

If you like biotech, buy it. Then be patient.

[mart] 09/5/2003 14:37

A bit more creep.

[21up] 08/5/2003 00:10

Creeping up

[mart] 01/5/2003 09:39

NAV now 92.76p!

[mart] 29/4/2003 09:49

To the top. Time to top up?

[rambutan2] 17/3/2003 23:18

the above mentioned announcement. its certainly a stonking deal...


more on...


of course ibt only owns a small percentage, having invested just over £3m, but thats over 10% of its mkt cap at mo and if eyetech gets through its phase iii trails, which given fast track status by fda, then its value will really soar. would then turn into a v profitable investment for ibt.

[rambutan2] 03/3/2003 15:57

a port co and still held at cost!
from redherring...

An aye for Eyetech
The startup pharmaceutical company takes on Alcon with its new drug for blindness.
By Eric W. Pfeiffer
February 27, 2003

This year more than a million people will watch--literally--as their central vision degrades. Many will go completely blind. But Eyetech Pharmaceuticals, founded in 2000 and based in New York, is working hard to avert this tragedy. Its new drug, Macugen, targets the 1.2 million elderly people in the United States alone who suffer from an eye disease called age-related macular degeneration (AMD).
The leading cause of vision loss in the elderly, AMD causes abnormal blood vessels to grow behind the retina, leaking blood and fluid over the area responsible for central vision. Current AMD treatment options, a drug called Visudyne or laser-cauterization of blood vessels, are ineffective and short-lived, says David Maris, an analyst with the investment bank Credit Suisse First Boston. But Macugen stops the leakage in old vessels and the growth of new vessels. The drug, which could also be used to treat blindness caused by diabetes, is now in the final stages of human trials. If everything goes according to plan (which almost never happens in biotech), the drug could be available in 2004.
Ophthalmology giant Alcon is likely to hit the market with its own AMD drug about the same time. "It's a two-horse race," says Mr. Maris. The Texas company will be stiff competition for Eyetech, even though the startup has what many consider one of the strongest teams in ophthalmology.
To bolster its competitive advantage, Eyetech last year announced a deal with Pfizer to jointly develop and market Macugen. Pfizer agreed to pay $100 million up front, and up to $645 million more if certain milestones are met. This is one of the largest deals of its kind ever between a private biotech firm and a large pharmaceutical company. Eyetech had previously raised a $108.5 million third round of funding led by JPMorgan Partners in 2001.
The company could grab half of the billion-dollar AMD treatment market, analysts say. And a $500 million drug is huge, even for a large pharmaceutical company. "Our mission is to become a leading ophthalmology company," says Eyetech's CEO, David Guyer. To do this, Eyetech will compete with others besides Alcon: Genentech has an AMD drug in clinical trials, and other startups are working on the next generation of treatments. But an initial success would open other avenues of growth, says Mr. Maris. "Eyetech could be another Genentech. The key is to get that first success."

[21up] 29/11/2002 20:21

phil Sorry can't help you.Some big trades going through today.

[patterbu] 18/11/2002 14:23

at a discount of about 30% to NAV, is this unusual?
phil

[21up] 07/11/2002 19:14

Net asset value-ON THE RISE,will keep monitoring this one.

[21up] 01/7/2002 21:13

I see the EXETER funds managers have been at it again.